SCHEDULE: Zenas BioPharma Stakeholder Sells Shares, Ownership Drops Below 5%

Zenas BioPharma's significant stakeholder, Zebra Aggregator, LP, has sold a substantial number of shares, reducing its beneficial ownership to below the 5% threshold.

Summary

• Amendment No. 2 to Schedule 13D has been filed by Enavate Sciences GP, LLC and Zebra Aggregator, LP regarding Zenas BioPharma, Inc.
• The reporting persons collectively beneficially own 3,245,404 shares of common stock, representing 4.9% of the outstanding shares as of July 31, 2026.
• This percentage is based on 65,176,723 shares outstanding, as reported in Zenas BioPharma's Form 10-Q filed on August 13, 2026.
• On August 19, 2026, Zebra LP sold 673,755 shares in an open market sale.
• The reporting persons ceased to be the beneficial owners of more than five percent of the common stock on August 19, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant sale of shares and the reporting person ceasing to be a beneficial owner of more than five percent, indicating a potential reduction in confidence or strategic shift.

Negatives

• Zebra Aggregator, LP sold 673,755 shares of Zenas BioPharma common stock on August 19, 2026.
• The reporting persons' beneficial ownership of Zenas BioPharma's common stock has fallen below the 5% threshold.
• The reporting persons are no longer considered beneficial owners of more than five percent of the common stock as of August 19, 2026.

Risks

• The sale of a significant number of shares by a major stakeholder could indicate a lack of confidence in the company's future prospects.
• A reduction in beneficial ownership below 5% may signal a strategic shift or divestment by the reporting persons.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from management regarding future performance. The primary information relates to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that significant share sales by major holders, especially those that push ownership below the 5% reporting threshold, can be interpreted by the market as a negative signal, potentially impacting investor sentiment and share price.

Stakeholder Impact

• Shareholders may view the significant sale by a major holder as a negative signal, potentially leading to increased selling pressure.
• The reduction in ownership by Enavate Sciences GP, LLC and Zebra Aggregator, LP may alter the influence of these entities on Zenas BioPharma's corporate decisions.

Key Dates

Recommendation

The filing indicates a significant reduction in beneficial ownership by a major stakeholder, which is a negative development. However, without further context on the reasons for the sale or the company's underlying performance, a 'hold' recommendation is prudent, suggesting investors monitor the situation for further information before making a decisive move.

Keywords

Zenas BioPharma, Schedule 13D, Beneficial Ownership, Shareholder, Stock Sale, Enavate Sciences, Zebra Aggregator